082800 — Vivozon Pharmaceutical Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapNeutral

Annual cashflow statement for Vivozon Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-44,085	-71,015	-39,234	-3,357	-9,982
Depreciation
Amortisation
Non-Cash Items	39,472	56,407	27,559	7,213	12,511
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	7,058	-8,441	4,708	-4,092	-362
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	4,625	-17,496	-3,323	2,992	5,731
Capital Expenditures	-1,197	-12,281	-8,643	-6,670	-10,538
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-62,987	-34,847	-25,909	25,979	4,164
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-64,184	-47,128	-34,552	19,309	-6,373
Financing Cash Flow Items	-1,800	-2,075	-4,503	-1,476	-1,605
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	67,235	13,515	26,391	-16,659	-819
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	7,000	-50,533	-11,448	5,635	-1,462